Lantus Stands Out in Study


By: W. Langbein

Nighttime relief is on the way.

A 756-patient study of Lantus (insulin glargine), the 24-hour basal insulin from Aventis, revealed that when compared to NPH, nearly 25 percent more patients in the Lantus group achieved the target A1C of 7 percent or less without an episode of nighttime hypoglycemia (low blood glucose).

The 24-week multi-center randomized study enrolled overweight type 2 men and women with inadequate blood glucose control (A1Cs greater than 7.5 percent) who were using one or two oral diabetes drugs. The added bedtime dose of either Lantus or NPH insulin was titrated as needed, seeking a target morning fasting blood glucose of 100 mg/dl or less.

-Diabetes Care, November 2003



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.